The Pfizer-backed Series C round will see Storm work out an accelerated approval pathway for STC-15 in sarcoma.

Tia Faye Clark says she visited seven medical professionals who dismissed her symptoms as a 'squishy' post-baby belly, until ...

In this phase 1 trial (NCT03715933), ozekibart is paired with the established chemotherapy duo of temozolomide and irinotecan ...

FDA orphan drug designation provides incentives including regulatory support, tax credits, fee exemptions, and seven years of ...

A new clinical trial led by the Penn State College of Medicine-based Beat Childhood Cancer Research Consortium will evaluate ...

Cancer patients at TGH benefit from clinical excellence, clinical trials and translational research. Tampa General Hospital’s ...

Paclitaxel remains first-line for cutaneous angiosarcoma, but absence of validated second-line therapy creates a major unmet need after progression or intolerance. A 30-patient, 15-center JCOG study ...

A new clinical trial is enrolling up to 60 children and young people with solid tumors across the United States and United ...

Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced updated interim data ...

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company advancing cancer treatments, ...

The massive surge was triggered by encouraging updated interim data from INBX’s phase I/II study evaluating ozekibart ...